Biodefense, Cellular Immunity, Infectious Disease, Influenza Virus, Interferon, Interferon Antagonists, Molecular Biology, Paramyxovirus, RNA, RNA Splicing & Processing, Signal Transduction, Transcription Factors, Vaccine Development, Viruses and Virology
Multi-Disciplinary Training Area
PhD, McGill University
, Harvard University
American Society of Virology Ann Palmenberg Award
American Society of Virology (ASV)
American Society of Gene and Cell Therapy Young Investigator Award
This award recognizes young investigators who have achieved exception technological advances in the field of gene and cell therapy.
Vilcek Award for Creative Promise
This prize recognizes foreign-born scientists who display exceptional creativity and originality in the early stages of their careers.
Investigator in the Pathogenesis of Infectious Diseases
Burroughs Wellcome Fund
Cozzarelli Prize Recipient in Biomedical Sciences
National Academy of Science
Young Investigator Award
American Society for Microbiology
Milstein Young Investigator Award
International Society of Interferon and Cytokine Research
Pew Charitable Trust in Biomedical Sciences
Presidential Early Career Award for Scientists and Engineers (PECASE)
National Science and Technology Council
Specific Clinical/Research Interests: Host-Pathogen Interactions
Current Students: Asiel Benitez, Lauren Aguado, Paul Leon
Postdoctoral Fellows: Sonja Schmid, Ryan Langlois, Simone Backes, Andrew Varble
Research Personnel: Maryline Panis, Jaehee Shim, Ismarc Ryes
The tenOever lab broadly focuses on the molecular interactions between viruses and their host. More specifically, the lab studies how the cell responds to virus. This research encompasses the study of cellular antiviral proteins and small RNAs, of both cellular and virus origin, which contribute to the outcome of infection. The overall objective of this lab is to gain a thorough understanding of the molecular basis of virus pathogenicity in an effort to generate improved vaccines and therapeutics.
Summary of Research Studies:
We focus on the interplay between RNA viruses and small RNAs. This research includes the study of microRNAs and virus-derived small RNAs and their role, if any, in the cellular response to infection. In addition, we exploit the small RNA machinery of the cell to control virus tropism, virus synthesis of miRNAs, and the biology of virus-derived small RNAs. Our laboratory uses several techniques to study these RNA-based host-virus interactions including genetic manipulation of both host and pathogen. We are presently working in the following areas.
Perez JT, Pham AM, Lorini MH, Chua MA, Steel J, tenOever BR. MicroRNA-Mediated Species-Specific Attenuation of Influenza A Virus. Nat Biotechnol 2009 Jun; 27(6): 572-576.
Perez JT, Varble A, Sachidanandam R, Zlatev I, Manoharan M, García-Sastre A, tenOever BR. Influenza A virus-generated small RNAs regulate the switch from transcription to replication. Proceedings of the National Academy of Sciences of the United States of America 2010 Jun; 107(25).
Shapiro JS, Varble A, tenOever BR. Non-Canonical Cytoplasmic Processing of Viral microRNAs. RNA 2010; 16: 2068-74.
Varble A, Chua MA, Perez JT, Manicassamy B, Garcia-Sastre A, tenOever BR. Engineered RNA Viral Synthesis of microRNAs. PNAS 2010; 107(25): 11519-24.
Schmid S, Mordstein M, Kochs G, Garcia-Sastre A, tenOever BR. Transcription Factor Redundancy Ensures Induction of the Antiviral State. JBC 2010; 285(53): 42013-22.
Langlois RA, Shapiro JS, Pham AM, tenOever BR. In vivo delivery of cytoplasmic RNA virus-derived miRNAs. Molecular therapy : the journal of the American Society of Gene Therapy 2012 Feb; 20(2).
Pham AM, Langlois RA, tenOever BR. Replication in cells of hematopoietic origin is necessary for Dengue virus dissemination. PLoS pathogens 2012 Jan; 8(1).
Shapiro JS, Langlois RA, Pham AM, tenOever BR. Evidence for a cytoplasmic microprocessor of pri-miRNAs. RNA (New York, N.Y.) 2012 Jul; 18(7).
Langlois RA, Varble A, Chua MA, García-Sastre A, tenOever BR. Hematopoietic-specific targeting of influenza A virus reveals replication requirements for induction of antiviral immune responses. Proceedings of the National Academy of Sciences of the United States of America 2012 Jul; 109(30).
Backes S, Shapiro JS, Sabin LR, Pham AM, Reyes I, Moss B, Cherry S, tenOever BR. Degradation of host microRNAs by poxvirus poly(A) polymerase reveals terminal RNA methylation as a protective antiviral mechanism. Cell host & microbe 2012 Aug; 12(2).
Perez JT, Zlatev I, Aggarwal S, Subramanian S, Sachidanandam R, Kim B, Manoharan M, tenOever BR. A small-RNA enhancer of viral polymerase activity. Journal of virology 2012 Dec; 86(24).
Chua MA, Schmid S, Perez JT, Langlois RA, tenOever BR. Influenza A Virus Utilizes Suboptimal Splicing to Coordinate the Timing of Infection. Cell reports 2013 Jan;.
tenOever BR. RNA viruses and the host microRNA machinery. Nature reviews. Microbiology 2013 Mar; 11(3).
Langlois RA, Albrecht RA, Kimble B, Sutton T, Shapiro JS, Finch C, Angel M, Chua MA, Gonzalez-Reiche AS, Xu K, Perez D, García-Sastre A, tenOever BR. MicroRNA-based strategy to mitigate the risk of gain-of-function influenza studies. Nature biotechnology 2013 Sep; 31(9).
Varble A, Benitez AA, Schmid S, Sachs D, Shim JV, Rodriguez-Barrueco R, Panis M, Crumiller M, Silva JM, Sachidanandam R, tenOever BR. An in vivo RNAi screening approach to identify host determinants of virus replication. Cell host & microbe 2013 Sep; 14(3).
Cullen BR, Cherry S, tenOever BR. Is RNA interference a physiologically relevant innate antiviral immune response in mammals?. Cell host & microbe 2013 Oct; 14(4).
Schmid S, Sachs D, tenOever BR. Mitogen-activated Protein Kinase-mediated Licensing of Interferon Regulatory Factor 3/7 Reinforces the Cell Response to Virus. The Journal of biological chemistry 2014 Jan; 289(1).
Schmid S, Zony LC, tenOever BR. A versatile RNA vector for delivery of coding and non-coding RNAs. Journal of Virology 2013 Dec;.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.tenOever did not report having any of the following types of financial relationships with industry during 2016 and/or 2017: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.